Generic drug maker Mylan turned itself into one of the largest makers of sterile injectable drugs last year with its $1.75 billion acquisition of Agila Specialties. Today the drugmaker pointed to one reason to take on all of that production capacity. Its earnings got a big boost from injectable products, in part because of drug shortages.
Labeling problems can lead to a recall, particularly when a drug is missing its expiration date labels--or some of the paper label pieces end up in vials. That is the scenario Mylan faces in recalling products made by Agila Specialties, the injectable drug company it bought last year for $1.7 billion.
Any industry that's undergoing as much change as biopharma is always looking for leadership. Old marketing practices are being blown apart, R&D is being subjected to emergency surgery, drug...
Last year, Roche appeared to throw in the towel on its breast cancer drug Herceptin in India when it said it would not defend the patent there. But it has come back out swinging with a court action that has messed with this week's launch of a biosimilar from Mylan.
Gilead Sciences and Mylan have for years had a deal for Mylan to make generic versions of some of Gilead's HIV drugs in markets around the world. Now Mylan will take over distribution of Gilead's branded products in India, a country where high-cost meds have sometimes met patent challenges.
Pfizer celebrated three birthdays January 1. That's when it officially divided its business into three distinct units, each with its own management and financial reporting--and each with its own prospect of setting off on its own, at least eventually. Analysts are betting that one of those three businesses will be first to go: Already, potential buyers are buzzing.
Mylan turned to India's Biocon last year for expertise on making biosimilars. This year, the generic drug maker is turning to Biocon for someone to run its extensive operations in that country.
Manufacturing facilities in India that are approved by Western regulators are a hot commodity, and that is what Bafna Pharmaceuticals has. The Indian drugmaker is for sale and is reportedly drawing interest from potential buyers, including Mylan as well as some Indian drugmakers.
Mylan said today that it and Indian biologics partner Biocon have nabbed the first approval in India and will have a biosimilar of Herceptin (trastuzumab) ready to roll out early next year.
Generic drugmaker Mylan is recalling 73 lots and more than 480,000 bottles of the generic blood pressure medicine amlodipine besylate.